Article Text

Download PDFPDF

1010 Tumor-specific CD4 T cells: the unexpected human cancer killers
  1. Mara Cenerenti1,2,3,
  2. Margaux Saillard-Salvi1,2,3,
  3. Paul Gueguen3,
  4. Romina Marone4,
  5. Yen-Cheng Liu5,
  6. Sabina Müller6,
  7. Salvatore Valitutti6,7,
  8. Hatice Altug6,
  9. Daniel Speiser8,
  10. Lukas Jeker4,
  11. Pedro Romero9,
  12. Santiago Carmona8 and
  13. Camilla Jandus1,2,3
  1. 1University of Geneva, Geneva, Switzerland
  2. 2Geneva Center for Inflammation Research, Geneva, Switzerland
  3. 3Ludwig Institute for Cancer Research, Lausanne, Switzerland
  4. 4University of Basel, Basel, Switzerland
  5. 5EPFL, Lausanne, Switzerland
  6. 6INSERM, Toulouse, France
  7. 7Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France
  8. 8University of Lausanne, Lausanne, Switzerland
  9. 9Novigenix, Epalinges, Switzerland
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background CD4 T cells help coordinating adaptive immune responses. Increasing evidence shows that antigen-specific CD4 T cells are also key players in anti-tumor immunity. We and others recently reported on the frequent existence of fully active, tumor-specific CD4 T cells with cytolytic properties in cancer patients. However, the molecular determinants regulating CD4 T cell cytotoxicity in cancer are poorly defined.

Methods Using peptide-MHC class II fluorescent multimers, we isolated tumor-specific CD4 T cells from peripheral blood and tumor tissues of cancer patients. These cells were classified as helper or cytolytic according to their ability to directly eliminate MHC class II-matched targets.

Results Next, by integrating ex vivo peripheral blood single cell and in situ spatial transcriptomics, we identified key molecules potentially involved in the cytolytic mechanism. To validate the relevance of these molecules in primary human CD4 T cells, we used either pharmacologic inhibitors or CRISPR/Cas9 technology. Killing capacity and immunological synapse formation of wild-type and inhibited/gene-edited cells are evaluated down to single cell level resolution using live cell imaging techniques. Ultimately, our findings will be validated in vivo by adoptive cell transfer of wild-type or gene-edited CD4 T cells in human tumor-bearing NSG mice.

Conclusions Overall, we will provide clues to exploit cytolytic CD4 T cells in the clinics alone or in combination with other cancer immunotherapies.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.